Literature DB >> 9273985

Cystic fibrosis and calcium oxalate nephrolithiasis.

A S Chidekel1, T F Dolan.   

Abstract

During the past six years, we have treated eight patients with cystic fibrosis (CF) for nephrolithiasis. In seven patients, the stones were comprised of calcium oxalate. Another six patients had calcium oxalate crystalluria. In our CF population of 140 patients, this represents a cumulative incidence of calcium oxalate nephrolithiasis of 5.7 percent and an additional 4.2 percent incidence of crystalluria. Experience with these patients is reviewed. Pancreatic insufficiency was universally associated with nephrolithiasis or crystalluria. Diabetes and cirrhosis were also common. Predisposing factors and potential mechanisms of stone disease in pancreatic insufficient CF patients are discussed, focusing on the relationship between fat malabsorption in CF to oxalate metabolism.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9273985      PMCID: PMC2589049     

Source DB:  PubMed          Journal:  Yale J Biol Med        ISSN: 0044-0086


  19 in total

1.  Metabolic basis of renal-stone disease.

Authors:  A E Broadus; S O Thier
Journal:  N Engl J Med       Date:  1979-04-12       Impact factor: 91.245

2.  Hyperoxaluria in patients with ileal resection: an abnormality in dietary oxalate absorption.

Authors:  D L Earnest; G Johnson; H E Williams; W H Admirand
Journal:  Gastroenterology       Date:  1974-06       Impact factor: 22.682

3.  Mechanism for hyperoxaluria in patients with ileal dysfunction.

Authors:  V S Chadwick; K Modha; R H Dowling
Journal:  N Engl J Med       Date:  1973-07-26       Impact factor: 91.245

4.  Intestinal oxalate absorption.

Authors:  H J Binder
Journal:  Gastroenterology       Date:  1974-09       Impact factor: 22.682

5.  Acquired hyperoxaluria and intestinal disease. Evidence that bile acid glycine is not a precursor of oxalate.

Authors:  A F Hofmann; M M Tacker; H Fromm; P J Thomas; L H Smith
Journal:  Mayo Clin Proc       Date:  1973-01       Impact factor: 7.616

6.  Acquired hyperoxaluria, nephrolithiasis, and intestinal disease. Description of a syndrome.

Authors:  L H Smith; H Fromm; A F Hofmann
Journal:  N Engl J Med       Date:  1972-06-29       Impact factor: 91.245

7.  Hyperuricosuria due to high-dose pancreatic extract therapy in cystic fibrosis.

Authors:  F B Stapleton; J Kennedy; S Nousia-Arvanitakis; M A Linshaw
Journal:  N Engl J Med       Date:  1976-07-29       Impact factor: 91.245

8.  Effect of bile salts and fatty acids on the colonic absorption of oxalate.

Authors:  J W Dobbins; H J Binder
Journal:  Gastroenterology       Date:  1976-06       Impact factor: 22.682

9.  Importance of the colon in enteric hyperoxaluria.

Authors:  J W Dobbins; H J Binder
Journal:  N Engl J Med       Date:  1977-02-10       Impact factor: 91.245

10.  Intestinal bile salts in cystic fibrosis: studies in the patient and experimental animal.

Authors:  J T Harries; D P Muller; J P McCollum; A Lipson; E Roma; A P Norman
Journal:  Arch Dis Child       Date:  1979-01       Impact factor: 3.791

View more
  6 in total

1.  Oxalate and calcium excretion in cystic fibrosis.

Authors:  M A Turner; D Goldwater; T J David
Journal:  Arch Dis Child       Date:  2000-09       Impact factor: 3.791

2.  Renal diseases in adults with cystic fibrosis: a 40 year single centre experience.

Authors:  M J Wilcock; A Ruddick; K M Gyi; M E Hodson
Journal:  J Nephrol       Date:  2015-02-25       Impact factor: 3.902

3.  Loss of Cystic Fibrosis Transmembrane Regulator Impairs Intestinal Oxalate Secretion.

Authors:  Felix Knauf; Robert B Thomson; John F Heneghan; Zhirong Jiang; Adedotun Adebamiro; Claire L Thomson; Christina Barone; John R Asplin; Marie E Egan; Seth L Alper; Peter S Aronson
Journal:  J Am Soc Nephrol       Date:  2016-06-16       Impact factor: 10.121

4.  Pathophysiology and Treatment of Enteric Hyperoxaluria.

Authors:  Celeste Witting; Craig B Langman; Dean Assimos; Michelle A Baum; Annamaria Kausz; Dawn Milliner; Greg Tasian; Elaine Worcester; Meaghan Allain; Melissa West; Felix Knauf; John C Lieske
Journal:  Clin J Am Soc Nephrol       Date:  2020-09-08       Impact factor: 8.237

5.  Urinary stone disease prevalence and associations in cystic fibrosis.

Authors:  Jonathan B Zuckerman; Eric N Taylor; Jeremy F Wright; Wendy Y Craig; F L Lucas; David S Goldfarb
Journal:  Urolithiasis       Date:  2021-02-06       Impact factor: 3.436

Review 6.  Understanding Cystic Fibrosis Comorbidities and Their Impact on Nutritional Management.

Authors:  Dhiren Patel; Albert Shan; Stacy Mathews; Meghana Sathe
Journal:  Nutrients       Date:  2022-02-28       Impact factor: 5.717

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.